1. Dendreon receives complete response letter from FDA for Provenge® biologics license application. Dendreon press release dated 9 May 2007 [cited 15 May 2007; available from: www.dendreon.com].
2. Sixth meeting of the Cancer Vaccine Consortium; 2006 November 10–11; Washington, DC. Final program and speaker slides available from: http://www.sabin.org/programs/cvc/cvc_meetings.html; 2006.
3. Bringing therapeutic cancer vaccines and immunotherapies through development to licensure: 2007 February 8–9. Final program available at https://cms.palladianpartners.com/cms/1156354418/home.htm#; videocast available at http://videocast.nih.gov/. Bethesda, MD; 2007.
4. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha;Vaishampayan;Clin Cancer Res,2002
5. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant;Mitchell;Cancer Res,1988